VERU-111 βIII/βIV-tubulin inhibitor RGNCY-0098
Per 10 mg
VERU-111 is a novel small molecule inhibitor of βIII/βIV-tubulin in pancreatic cancer. βIII/βIV-tubulin isoforms have been mostly implicated in PanCa progression, metastases and chemo-resistance. VERU-111 preferentially represses clinically important βIII and βIV tubulin isoforms by restoring miR-200c expression. Consequently, VERU-111 significantly inhibited tumorigenic and metastatic characteristics of PanCa cells. VERU-11 also arrested the cell cycle in the G2/M phase and induced apoptosis in the PanCa cells by modulating cell cycle regulatory (Cdc2, Cdc25c, and Cyclin B1) and apoptosis associated (Bax, Bad, Bcl-2 and Bcl-xl) proteins. In addition, treatment with VERU-111 inhibited tumor growth (P<0.01) in a PanCa xenograft mouse model (AsPC-1). VERU-11 has significant therapeutic potential in PanCa treatment.
Systematic Name: (2-(1H-indol-3-yl)-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone
Mol Wt: 377.40
Therapeutic efficacy of a novel βIII/βIV-tubulin inhibitor (VERU-111) in pancreatic cancer. J Exp Clin Cancer Res. 2019 Jan 23;38(1):29. doi: 10.1186/s13046-018-1009-7.
There are no uploaded files